|
|
Silk Road Medical Inc (SILK) |
|
Price: $16.0400
$0.33 
2.101%
|
| Day's High:
| $16.24
| Week Perf:
| -2.31 %
|
| Day's Low: |
$ 15.28 |
30 Day Perf: |
-22.4 % |
| Volume (M): |
515 |
52 Wk High: |
$ 57.96 |
| Volume (M$): |
$ 8,256 |
52 Wk Avg: |
$39.19 |
| Open: |
$15.58 |
52 Wk Low: |
$15.03 |
|
|
| Market Capitalization (Millions $) |
622 |
| Shares
Outstanding (Millions) |
39 |
| Employees |
300 |
| Revenues (TTM) (Millions $) |
163 |
| Net Income (TTM) (Millions $) |
-53 |
| Cash Flow (TTM) (Millions $) |
-59 |
| Capital Exp. (TTM) (Millions $) |
3 |
Silk Road Medical Inc
Silk Road Medical Inc is a medical technology company that specializes in developing and commercializing novel devices and treatment options for patients suffering from vascular diseases. It was founded in Silicon Valley in 2007, and has rapidly risen to become a trusted brand in the healthcare industry.
The company's flagship product is the ENROUTE' Transcarotid Stent System, which is used to treat carotid artery disease, a potentially deadly condition that can lead to stroke. The ENROUTE' technology offers a minimally invasive solution for patients that enables the treatment of carotid artery disease without the need for open surgery.
The Silk Road Medical team comprises world-renowned experts in vascular surgery, interventional cardiology, and biomedical engineering. The company's research is backed by a comprehensive intellectual property portfolio that includes patents, trade secrets, and trademarks.
Silk Road Medical has established a global network of distribution partners to ensure that its medical devices reach the widest possible audience. The company has commercial offices in Europe and Asia, as well as in the United States. Additionally, Silk Road Medical has a robust digital platform that allows physicians and patients to access medical information, clinical studies, and educational resources.
The company has received numerous accolades for its innovation, including the Scientific Achievement Award from the Society for Vascular Surgery. Silk Road Medical has also been recognized by major publications such as Forbes and Inc. Magazine for its growth and impact on the healthcare industry.
In summary, Silk Road Medical Inc is a highly respected medical technology company that is dedicated to improving the lives of patients with vascular diseases through innovative solutions, advanced research, and education.
Company Address: 1213 Innsbruck Dr. Sunnyvale 94089 CA
Company Phone Number: 720-9002 Stock Exchange / Ticker: NASDAQ SILK
| SILK is expected to report next financial results on November 08, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Heart Test Laboratories Inc
Heart Test Laboratories Inc, a medical device manufacturing company, recently released its financial results for the first quarter of the 2024 earnings season. The figures demonstrate a significant decrease in loss per share compared to the previous year, as well as an improvement in earnings per share. Although the revenue remained unchanged, the company reported a lower net shortfall compared to the same reporting season the previous year. This article aims to provide an overview of Heart Test Laboratories Inc's Q1 2024 financial results and analyze them within the context of recent stock performance.
Financial Results:
Heart Test Laboratories Inc reported a loss per share of $-0.13 in the first quarter of 2024, a considerable improvement from the loss per share of $-0.28 in the same reporting season the previous year. Additionally, the company's earnings per share increased from $-0.16 in the previous reporting season. Despite these positive developments, the revenue for Q1 2024 remained unchanged at $0.00 million, both compared to the same reporting season a year before and sequentially.
|
|
Sensasure Technologies Inc
Date: August 1, 2023
As the financial interval closing July 31, 2023 draws to a close, Sensasure Technologies Inc, a leading technology company, has achieved a significant milestone by reaching break-even at $0.00 per share. This marks an improvement from the same reporting period a year ago when the company also reported a break-even, and from the preceding reporting period.
However, while this is an encouraging development for Sensasure Technologies Inc, it is crucial to examine the context of the financial results to gain deeper insights.
|
|
Innovage Holding Corp
Innovage Holding Corp, a Medical Equipment and Supplies company, recently released its financial results for the fourth quarter of 2023. Despite reporting a loss of $0.08 per share, compared to $0.09 in the previous year, the company's revenue grew moderately by 2.322% to $176.87 million.
However, this revenue surge was lower than the average growth rate of 4.80% for the Medical Equipment and Supplies sector during the same period. Analysts believe that this slower growth may be due to a decline in demand, as evidenced by the decrease in accounts receivable to $24.3 million.
|
|
Lakeland Industries Inc
Lakeland Industries Inc, a leading Medical Equipment and Supplies company, has delivered impressive financial results for the most recent fiscal period, outpacing its industry contemporaries. The company reported a positive bottom-line of $0.32 per share, a significant improvement compared to the negative $0.11 per share from the previous year. This translates to a staggering 77.78% increase in earnings per share from $0.18 in the previous reporting period.
The revenue growth for Lakeland Industries Inc has been equally impressive, with a substantial increase of 17.34% to $33.07 million from $28.18 million in the corresponding period a year ago. Moreover, their sequential revenue growth improved by 15.23% from $28.70 million. In sharp contrast, the rest of the Medical Equipment and Supplies industry only witnessed a 4.18% revenue improvement during the same period. This clearly highlights Lakeland Industries Inc's exceptional performance in the market.
|
|
The Cooper Companies Inc
Medical Equipment and Supplies Company, The Cooper Companies Inc, experienced a decline in earnings per share (EPS) despite a rise in revenue for the financial period ending on July 31, 2023. Although revenue increased by a significant 10.268% to $930.00 million compared to the previous year, income fell by -13.64% to $1.71 per share.
Despite the decline in EPS, the company's revenue surge in the third quarter of 2023 surpassed its industry peers, which only experienced a 4.05% overall business increase during the same period. Comparing to the previous reporting period, EPS showed impressive growth of 113.75% from $0.80 per share, while revenue improved by 5.995% from $877.40 million.
However, net earnings declined by -13.31% to $85.300 million at the end of July, compared to $98.400 million in the same period a year earlier. The Cooper Companies Inc focused on improving sales during the financial period, leading to a net margin decrease to 9.17%. Additionally, there has been a noticeable buildup in inventories, with inventories and supplies reaching $723.6 million, higher than the previous and corresponding quarter of the previous year.
On a positive note, operating earnings rose by 7.82% to $151.6 million. The increase in accounts receivable also indicates rising demand, with a value of $629.9 million, higher than the preceding quarter.
Looking into the future performance, The Cooper Companies Inc shares recorded a decline of -0.19% over the past five trading days, resulting in a year-to-date performance of 11.63%. The shares are currently 7.1% short of the 52-week highInvestors will be eagerly waiting to see the next financial numbers from The Cooper Companies Inc, which are expected to be reported on December 08, 2023. With a focus on improving sales and a noticeable buildup in inventories and accounts receivable, the company may be positioning itself for future growth despite the recent decline in EPS.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.4 $ |
| Revenues (TTM) |
4.2 $
|
| Cash Flow (TTM) |
- |
| Cash |
4.86 $
|
| Book Value |
4.01 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.4 $
|
| Revenues (TTM) |
4.2 $ |
| Cash Flow (TTM) |
- |
| Cash |
4.86 $
|
| Book Value |
4.01 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
